The global insulin drugs and delivery devices market size is calculated at USD 25.53 billion in 2025 and is forecasted to reach around USD 49.39 billion by 2034, accelerating at a CAGR of 7.61% from 2025 to 2034. The North America market size surpassed USD 8.30 billion in 2024 and is expanding at a CAGR of 7.76% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Insulin Drugs and Delivery Devices Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Insulin Drugs and Delivery Devices Market Revenue and Volume Forecast, by Product Type
8.1.1. Insulin Drugs
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Insulin Delivery Devices
8.1.2.1. Market Revenue and Volume Forecast
9.1. Insulin Drugs and Delivery Devices Market Revenue and Volume Forecast, by Diabetes Type
9.1.1. Type 1 Diabetes
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Type 2 Diabetes
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Gestational Diabetes
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Others (e.g., steroid-induced, MODY)
9.1.4.1. Market Revenue and Volume Forecast
10.1. Insulin Drugs and Delivery Devices Market Revenue and Volume Forecast, by End User
10.1.1. Hospitals
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Diabetes Clinics/Centers
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Homecare Settings
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Volume Forecast
11.1. Insulin Drugs and Delivery Devices Market Revenue and Volume Forecast, by Distribution Channel
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Online Sales
11.1.3.1. Market Revenue and Volume Forecast
11.1.4. Direct Tender/Bulk Procurement
11.1.4.1. Market Revenue and Volume Forecast
11.1.5. Others
11.1.5.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Product Type
12.1.2. Market Revenue and Volume Forecast, by Diabetes Type
12.1.3. Market Revenue and Volume Forecast, by End User
12.1.4. Market Revenue and Volume Forecast, by Distribution Channel
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Product Type
12.1.5.2. Market Revenue and Volume Forecast, by Diabetes Type
12.1.5.3. Market Revenue and Volume Forecast, by End User
12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Product Type
12.1.6.2. Market Revenue and Volume Forecast, by Diabetes Type
12.1.6.3. Market Revenue and Volume Forecast, by End User
12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Product Type
12.2.2. Market Revenue and Volume Forecast, by Diabetes Type
12.2.3. Market Revenue and Volume Forecast, by End User
12.2.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Product Type
12.2.5.2. Market Revenue and Volume Forecast, by Diabetes Type
12.2.5.3. Market Revenue and Volume Forecast, by End User
12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Product Type
12.2.6.2. Market Revenue and Volume Forecast, by Diabetes Type
12.2.6.3. Market Revenue and Volume Forecast, by End User
12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Product Type
12.2.7.2. Market Revenue and Volume Forecast, by Diabetes Type
12.2.7.3. Market Revenue and Volume Forecast, by End User
12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Product Type
12.2.8.2. Market Revenue and Volume Forecast, by Diabetes Type
12.2.8.3. Market Revenue and Volume Forecast, by End User
12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Product Type
12.3.2. Market Revenue and Volume Forecast, by Diabetes Type
12.3.3. Market Revenue and Volume Forecast, by End User
12.3.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Product Type
12.3.5.2. Market Revenue and Volume Forecast, by Diabetes Type
12.3.5.3. Market Revenue and Volume Forecast, by End User
12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Product Type
12.3.6.2. Market Revenue and Volume Forecast, by Diabetes Type
12.3.6.3. Market Revenue and Volume Forecast, by End User
12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Product Type
12.3.7.2. Market Revenue and Volume Forecast, by Diabetes Type
12.3.7.3. Market Revenue and Volume Forecast, by End User
12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Product Type
12.3.8.2. Market Revenue and Volume Forecast, by Diabetes Type
12.3.8.3. Market Revenue and Volume Forecast, by End User
12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Product Type
12.4.2. Market Revenue and Volume Forecast, by Diabetes Type
12.4.3. Market Revenue and Volume Forecast, by End User
12.4.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Product Type
12.4.5.2. Market Revenue and Volume Forecast, by Diabetes Type
12.4.5.3. Market Revenue and Volume Forecast, by End User
12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Product Type
12.4.6.2. Market Revenue and Volume Forecast, by Diabetes Type
12.4.6.3. Market Revenue and Volume Forecast, by End User
12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Product Type
12.4.7.2. Market Revenue and Volume Forecast, by Diabetes Type
12.4.7.3. Market Revenue and Volume Forecast, by End User
12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Product Type
12.4.8.2. Market Revenue and Volume Forecast, by Diabetes Type
12.4.8.3. Market Revenue and Volume Forecast, by End User
12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Product Type
12.5.2. Market Revenue and Volume Forecast, by Diabetes Type
12.5.3. Market Revenue and Volume Forecast, by End User
12.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Product Type
12.5.5.2. Market Revenue and Volume Forecast, by Diabetes Type
12.5.5.3. Market Revenue and Volume Forecast, by End User
12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Product Type
12.5.6.2. Market Revenue and Volume Forecast, by Diabetes Type
12.5.6.3. Market Revenue and Volume Forecast, by End User
12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel
13.1. Novo Nordisk A/S
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial PerProduct Typeance
13.1.4. Recent Initiatives
13.2. Eli Lilly and Company
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial PerProduct Typeance
13.2.4. Recent Initiatives
13.3. Sanofi
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial PerProduct Typeance
13.3.4. Recent Initiatives
13.4. Medtronic plc
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial PerProduct Typeance
13.4.4. Recent Initiatives
13.5. Insulet Corporation
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial PerProduct Typeance
13.5.4. Recent Initiatives
13.6. Tandem Diabetes Care, Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial PerProduct Typeance
13.6.4. Recent Initiatives
13.7. Ypsomed AG
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial PerProduct Typeance
13.7.4. Recent Initiatives
13.8. Biocon Biologics Ltd.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial PerProduct Typeance
13.8.4. Recent Initiatives
13.9. Wockhardt Ltd.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial PerProduct Typeance
13.9.4. Recent Initiatives
13.10. Becton, Dickinson and Company (BD)
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial PerProduct Typeance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description